Arrowhead Pharmaceuticals (ARWR) Stock Overview
Develops medicines for the treatment of intractable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ARWR Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.08 |
| 52 Week High | US$29.34 |
| 52 Week Low | US$9.57 |
| Beta | 1.01 |
| 1 Month Change | 78.26% |
| 3 Month Change | 72.96% |
| 1 Year Change | 30.85% |
| 3 Year Change | -24.62% |
| 5 Year Change | -12.45% |
| Change since IPO | -44.09% |
Recent News & Updates
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Sep 03Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
Aug 21
Recent updates
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Sep 03Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
Aug 21
Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles
Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry
May 14Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 03Arrowhead Pharmaceuticals Is Finally Arriving
Mar 21Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Feb 19Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns
Feb 10Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Shareholder Returns
| ARWR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 32.0% | 3.3% | 0.4% |
| 1Y | 30.9% | -2.9% | 21.6% |
Return vs Industry: ARWR exceeded the US Biotechs industry which returned -6% over the past year.
Return vs Market: ARWR exceeded the US Market which returned 19.5% over the past year.
Price Volatility
| ARWR volatility | |
|---|---|
| ARWR Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARWR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARWR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 609 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| ARWR fundamental statistics | |
|---|---|
| Market cap | US$3.87b |
| Earnings (TTM) | -US$148.42m |
| Revenue (TTM) | US$572.98m |
Is ARWR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARWR income statement (TTM) | |
|---|---|
| Revenue | US$572.98m |
| Cost of Revenue | US$0 |
| Gross Profit | US$572.98m |
| Other Expenses | US$721.39m |
| Earnings | -US$148.42m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 100.00% |
| Net Profit Margin | -25.90% |
| Debt/Equity Ratio | 115.5% |
How did ARWR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 23:10 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arrowhead Pharmaceuticals, Inc. is covered by 32 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |